Loading
A phase 3 trial testing Quemliclustat in pancreatic ductal adenocarcinoma, active and no longer recruiting.
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma is a phase 3 interventional study registered as NCT06608927, led by Arcus Biosciences with Taiho Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 610 participants (estimated). The study started in 2024-12-13 and primary completion is expected in 2030-11-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/